MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.
|Videos|July 6, 2017
Using Behavior Change Interventions to Strengthen Antibiotic Prescribing Practices
Author(s)Contagion Editorial Staff
Conan MacDougall, PharmD, explains what individuals should consider when it comes to adopting interventions in antibiotic stewardship programs.
Advertisement
Conan MacDougall, PharmD, professor of clinical pharmacy, University of California, San Francisco, explains what individuals should consider when it comes to adopting interventions in antibiotic stewardship programs.
Interview Transcript (slightly modified for readability)
“The take home message that I’d like people to think about when they’re considering how to affect positive behavioral change, is really changing the antibiotic prescribing environment. What are the choices that our clinicians are presented with when they’re picking an antibiotic? Even something like, what button is presented first in a list of antibiotic choices, or [is] an antibiotic selected by default? Those have very powerful effects and require very little effort, and so those are the types of interventions that we may need to adopt going forward, as we expand antimicrobial stewardship programs.”
Advertisement
Related to this article
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
4
Novel RSV Therapy: Addressing a Clinical Need
5